ARCHIVES

ColoPrint Improves Prognosis In Stage II and III Colon Cancer

This article is from The Cancer Letter archive.

Vol. 34 No. 1 | January 28, 2011

Download PDF Visit The Full Archive

Related Articles

Particle Therapy Program Would cost $600 million Over 10 Years for 16 Facilities, Clinical Trials

December 2, 1977

Sequestration: $1.71 Billion Cut to NIH Budget Will Reduce Number of RPGs

May 17, 2013

NCI’s Rosenberg Confirms 2002 Immunotherapy Results

April 29, 2005

Advisors Approve CCOP, EDRN, Pediatric Brain Tumor Network Renewal

March 28, 2003

Facilities Survey To Include All Institutions With $200,000 Or More in NCI Support

October 5, 1984

Navelbine+Herceptin: 78% Response In Breast Cancer

November 29, 2002